Drug ‘breakthrough’ gives longest-ever survival in non-resectable liver cancer patients
The IMbrave150 trial found median overall survival was 19.2 months in patients treated with atezo…
Browsing: Atezolizumab
Proton pump inhibitors may affect responses to atezolizumab in patients with urothelial cancer
PPIs are commonly used medications for acid reflux, heartburn, and ulcers. Recent evidence indicates that…
AACR 2020: Personalised cancer vaccine plus atezolizumab shows clinical activity in patients with advanced solid tumours
Treatment with the personalised cancer vaccine RO7198457 in combination with the PD-L1 inhibitor atezolizumab (Tecentriq)…
New treatment extends lives of people with most common type of liver cancer
For the first time in over a decade, scientists have identified a first-line treatment that…
Protected: TECENTRIQ® (atezolizumab) first immunotherapy to be reimbursed for 1L treatment of extensive-stage small cell lung cancer
This content is password protected. To view it please enter your password below: Password:
ASCO GI: New drug combinations maintain quality of life for patients with colorectal and liver cancers
Patient-reported outcomes from two large studies show that quality of life is maintained longer with…
Combining atezolizumab with neoadjuvant chemotherapy does not improve pathologic complete response rates for patients with triple-negative breast cancer
The addition of the anti-PD-L1 immunotherapeutic atezolizumab to neoadjuvant chemotherapy for patients with triple-negative breast…
Findings could identify aggressive breast cancers that will respond to immunotherapy
University of North Carolina Lineberger Comprehensive Cancer Center, USA, researchers have discovered a promising method…
Protected: Tecentriq® (atezolizumab) + chemotherapy now TGA approved for 1L extensive-stage small cell lung cancer
This content is password protected. To view it please enter your password below: Password:
Atezolizumab combination improves PFS for advanced NSCLC patients
Findings from a recent study demonstrate that the use of atezolizumab, a PD-L1 inhibitor, in…